Last reviewed · How we verify
NCT03982394: VALUE
Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis
trial in Chronic Plaque Psoriasis in 2,759 participants. Completed in 2 September 2025.
2 September 2025
Quick facts
| Lead sponsor | AbbVie |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,759 |
| Start date | 1 July 2019 |
| Primary completion | 2 September 2025 |
| Estimated completion | 2 September 2025 |
| Sites | 302 locations across Italy, Colombia, Japan, Ireland, Poland, Netherlands, Mexico, France |
Conditions studied
- Chronic Plaque Psoriasis — all drugs for Chronic Plaque Psoriasis →
Sponsor
AbbVie — full company profile →
Who can join
18 and older, any sex, with Chronic Plaque Psoriasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will assess the use of risankizumab in adult patients with moderate to severe chronic plaque psoriasis and compare risankizumab to other commonly used biologics.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasis.
Gooderham MJ, Lynde C, Turchin I, Avadisian M, et al · · 2022 · cited 16× · PMID 34747071 · DOI 10.1111/1346-8138.16214 -
Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months.
Thaçi D, Ohtsuki M, Maul JT, Szegedi A, et al · · 2025 · cited 7× · PMID 39904971 · DOI 10.1007/s13555-025-01342-0
Verify or expand the search:
- PubMed search for NCT03982394
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Plaque Psoriasis
Currently open trials in the same condition.
- NCT07337434 — To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Present · EARLY_PHASE1 · recruiting
Other AbbVie trials
Trials by the same sponsor.
- NCT07219017 — A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants · Phase 1 · completed
- NCT05316220 — A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years W · Phase 3 · withdrawn
- NCT07024797 — Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult · Phase 1 · completed
- NCT07058051 — Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China · completed
- NCT07007091 — A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03982394 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AbbVie
- Last refreshed: 17 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03982394.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing